PNDX-B 📈 Pandox AB (publ) - Overview
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0007100359
PNDX-B: Hotel Rooms, Hotel Properties, Hotel Leases, Property Development
Pandox AB (publ) is a prominent hotel property company with a global presence, specializing in the ownership, development, and leasing of hotel properties. The company's operations are divided into two distinct segments: Leases and Own Operations. The Leases segment focuses on leasing hotels to established hotel operators, providing them with high-quality properties in prime locations. This approach enables Pandox to generate stable revenue streams while allowing hotel operators to focus on their core business. On the other hand, the Own Operations segment involves the direct ownership and operation of hotel properties, giving Pandox full control over the management and strategy of these assets.
With a rich history dating back to 1932, Pandox has established itself as a major player in the global hotel property market. Headquartered in Stockholm, Sweden, the company has developed a strong reputation for its expertise in hotel property development, ownership, and operation. Pandox's commitment to delivering high-quality properties and services has earned it a loyal customer base and a strong market position. For investors, Pandox offers a unique opportunity to participate in the growth and development of the hotel property sector, with its common stock listed under the ISIN code SE0007100359 and classified as a Real Estate Operating Company within the GICS Sub Industry.
Pandox's business model is designed to provide a balance between stability and growth, with a focus on long-term value creation. By combining its leasing and own operations segments, the company is able to diversify its revenue streams and mitigate risks. This approach, combined with its extensive industry expertise and global presence, has enabled Pandox to establish itself as a leader in the hotel property sector. For more information about Pandox and its operations, investors and stakeholders can visit the company's website at https://www.pandox.se, which provides detailed information about its business, financial performance, and growth strategy.
Additional Sources for PNDX-B Stock
PNDX-B Stock Overview
Market Cap in USD | 3,159m |
Sector | Real Estate |
Industry | Real Estate Services |
GiC Sub-Industry | Real Estate Operating Companies |
IPO / Inception |
PNDX-B Stock Ratings
Growth 5y | 16.7% |
Fundamental | 10.6% |
Dividend | 38.4% |
Rel. Strength Industry | 550 |
Analysts | - |
Fair Price Momentum | 158.85 SEK |
Fair Price DCF | 64.68 SEK |
PNDX-B Dividends
Dividend Yield 12m | 2.24% |
Yield on Cost 5y | 1.99% |
Annual Growth 5y | 2.13% |
Payout Consistency | 67.3% |
PNDX-B Growth Ratios
Growth Correlation 3m | -41.5% |
Growth Correlation 12m | 71.5% |
Growth Correlation 5y | 41.3% |
CAGR 5y | -2.15% |
CAGR/Mean DD 5y | -0.06 |
Sharpe Ratio 12m | 0.98 |
Alpha | -1.68 |
Beta | 1.34 |
Volatility | 28.00% |
Current Volume | 109k |
Average Volume 20d | 243.3k |
As of January 15, 2025, the stock is trading at SEK 182.60 with a total of 109,048 shares traded.
Over the past week, the price has changed by -4.70%, over one month by -7.08%, over three months by -14.55% and over the past year by +29.37%.
Neither. Based on ValueRay Fundamental Analyses, Pandox AB (publ) is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 10.56 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PNDX-B as of January 2025 is 158.85. This means that PNDX-B is currently overvalued and has a potential downside of -13.01%.
Pandox AB (publ) has no consensus analysts rating.
According to ValueRays Forecast Model, PNDX-B Pandox AB (publ) will be worth about 173 in January 2026. The stock is currently trading at 182.60. This means that the stock has a potential downside of -5.24%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 225 | 23.2% |
Analysts Target Price | - | - |
ValueRay Target Price | 173 | -5.2% |